Kurse werden geladen...
Prognose
Das durchschnittliche Kursziel der Analysten beträgt 6,44€(−3,01%). Der Median liegt bei 5,70€(−14,16%).
Kaufen | 5 |
Halten | 1 |
Verkaufen | 2 |
Scoring-Modelle
Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.
News
Telomir Pharmaceuticals Announces Telomir-1 Resets the Body's Epigenetic Clock, Reverses DNA Methylation, and Restores Youthful Gene Regulation in an Ultra-Rare Accelerated Aging Animal Model of Werner Syndrome
Treatment restored gene control, extended telomere length beyond healthy levels, reversed muscle and weight loss, reduced oxidative stress, and resulted in 100% survival - highlighting Telomir-1's potential to reverse key hallmarks of aging MIAMI, FL / ACCESS Newswire / June 5, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or the "Company," an emerging leader in age-reversal science, today announced compelling new preclinical data demonstrating that its lead candidate, Telomir-1, administered orally, significantly increases telomere length, reverses body weight and muscle loss, and resets cellular aging markers in a validated animal model of Werner Syndrome (WS)-a rare genetic disorder also known as adult-onset progeria. These findings confirm and build upon the Company's previously reported results from a preclinical C.» Mehr auf accessnewswire.com
Applied DNA Announces 1-For-15 Reverse Stock Split Effective June 2, 2025
STONY BROOK, NY / ACCESS Newswire / May 29, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced that it will effect a 1-for-15 reverse stock split of its issued and outstanding common stock. The Reverse Stock Split will become effective at 12:01 a.m.» Mehr auf accessnewswire.com
Telesis Bio Announces Licensing Agreement with Regeneron to Adopt Gibson SOLA™ Platform for Rapid On-Site DNA and Gene Synthesis
SAN DIEGO--(BUSINESS WIRE)--Telesis Bio Inc. (OTCMKTS: TBIO), a leading provider of DNA and mRNA synthesis solutions to accelerate therapeutic discovery with fast and flexible on-site automated foundries, today announced a new license agreement with Regeneron Pharmaceuticals, Inc. to deploy Telesis Bio's revolutionary Gibson SOLA™ platform at its R&D core facilities. This will help Regeneron adopt automated, high-throughput, on-demand gene synthesis in their own labs. Using Gibson SOLA at s.» Mehr auf businesswire.com
Unternehmenszahlen
(EUR) | März 2025 | |
---|---|---|
Umsatz | 44,66 Mio | 27,04% |
Bruttoeinkommen | 33,53 Mio | 127,96% |
Nettoeinkommen | −84,08 Mio | 45,31% |
EBITDA | −63,16 Mio | 58,72% |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 389,55 Mio€ |
Anzahl Aktien | 58,53 Mio |
52 Wochen-Hoch/Tief | 19,82€ - 4,38€ |
Dividenden | Nein |
Beta | 1,26 |
KGV (PE Ratio) | −0,87 |
KGWV (PEG Ratio) | −0,06 |
KBV (PB Ratio) | 0,64 |
KUV (PS Ratio) | 1,87 |
Unternehmensprofil
Name | Ginkgo Bioworks Holdings A Aktie |
CEO | Dr. Jason Kelly Ph.D. |
Mitarbeiter | 834 |
Assets entdecken
Shareholder von Ginkgo Bioworks Holdings A Aktie investieren auch in folgende Assets